Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 8
Submit an article Journal homepage
228
Views
107
CrossRef citations to date
0
Altmetric
Review

Chemotherapy for major food-borne trematodes: a review

Jennifer Keiser Swiss Tropical Institute, PO Box, CH–4002 Basel, Switzerland. [email protected]
&
Jürg Utzinger Swiss Tropical Institute, PO Box, CH–4002 Basel, Switzerland.
Pages 1711-1726 | Published online: 25 Feb 2005

Bibliography

  • ABDUSSALAM M, KAFERSTEIN FK,MOTT KE: Food safety measures for the control of foodborne trematode infections. Food Control (1995) 6:71–79.
  • •A good review on food safety measures and research needs for the prevention and control of food-borne trematodiasis.
  • WHO: Control of foodborne nematode infections. Report of a WHO study group. WHO Techn. Rep. Ser. No. 849. World Health Organization, Geneva (1995).
  • ••An authoritative review covering all aspectsof the epidemiology and control of food-borne trematodiasis as of the early 1990s.
  • CROMPTON DW: How much human helminthiasis is there in the world? Parasitol (1999) 85:397–403.
  • GRACZYK TK, GILMAN RH, FRIED B: Fasciolopsiasis: is it a controllable food-borne disease? Parasitol Res. (2001) 87:80–83.
  • •A good review on fasciolopsiasis.
  • CHAT JY, LEE SH: Food-borne intestinal trematode infections in the Republic of Korea. Parasitol Int. (2002) 51:129–154.
  • ••An excellent review on the biology, clinicalaspects, epidemiology, host-parasite cross-talks and taxonomy of intestinal fluke infections in the Republic of Korea.
  • ESTEBAN J-G, GONZALEZ C, CURTALE F et al.: Hyperendemic fascioliasis associated with schistosomiasis in villages in the Nile Delta of Egypt. Am. Trop. Med. Hyg. (2003) 69:429–437.
  • •The first report on a significant positive association between Fasciola infection and S. mansoni, and implications for diagnosis, pathology and therapy.
  • HASWELL-ELKINS M, LEVRI E: Food-borne Trematodes. In: Manson's Tropical Diseases (21" edn). Cook G, Zumla A (Eds), WB Saunders, London, UK (2003).
  • ••An excellent book chapter with comprehensive and up-to-date reviews on the major food-borne trematode infections.
  • DASZAK P, CUNNINGHAM AA: Anthropogenic change, biodiversity loss, and a new agenda for emerging diseases. .1 Parasitol (2003) 89(Suppl.):S37–S41.
  • WALLACE BJ, GUZEWICH JJ, CAMBRIDGE M, ALTEKRUSE S, MORSE DL: Seafood-associated disease outbreaks in New York, 1980-1994. Am.j Prey Med. (1999) 17:48–54.
  • MURRELL KD, CROSS JH, LOOAREESUWAN S: Food- and water-borne parasitic zoonoses in the 21st century. Trends Parasitol (2001) 17:163–164.
  • FRIED B, GRACZYK TK, TAMANG L: Food-borne intestinal trematodiasis in humans. Parasitol Res. (2004) 93:159–170.
  • ••Paper provides a wealth of information onoften neglected intestinal fluke infections, including human disease, economic impact, diagnosis and treatment, prevention and control.
  • RADOMYOS B, WONGSAROJ T, WILAIRATANA P et al.: Opisthorchiasis and intestinal fluke infections in northern Thailand. SoutheastAsianj Trop. Med. Public Health (1998) 29:123–127.
  • SITHITHAWORN P, HASWELL-ELKINS M: Epidemiology of Opisthorchis viverrini. Acta Trop. (2003) 88:187–194.
  • •A good summary on the epidemiology of O. viverrini with particular emphasis on Thailand.
  • RIM HJ, FARAG HF, SORNMANI S, CROSS JH: Food-borne trematodes: ignored or emerging? Parasitol Today (1994) 10:207–209.
  • LOAHARANU P, SORNMANI S: Preliminary estimates of economic impact of liver fluke infection in Thailand and the feasibility of irradiation as a control measure. SoutheastAsianj Trop. Med. Public Health (1991) 22:384–390.
  • YU S, MOTT K: Epidemiology and morbidity of food-borne intestinal trematode infections. Trop. Dis. Bull. (1994) 91:125–152.
  • WHO: Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Techn. Rep. Ser. No. 912. World Health Organization, Geneva (2002).
  • •An authoritative report laying out the WHO dual strategy to control schistosomiasis and soil-transmitted helminthiasis.
  • FENWICK A, SAVIOLI L, ENGELS D, BERGQUIST NR, TODD MH: Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol (2003) 19:509–515.
  • SAVIOLI L, ALBONICO M, ENGELS D, MONTRESOR A: Progress in the prevention and control of schistosomiasis and soil-transmitted helminthiasis. Parasitol Int. (2004) 53:103–113.
  • UTZINGER J, KEISER J: Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin. Pharmacother: (2004) 5:263–285.
  • •A comprehensive review on the current arsenal of drugs for the treatment and control of schistosomiasis and soil-transmitted helminthiasis.
  • HAWN TR, JONG EC: Update on hepatobiliary and pulmonary flukes. Curr. Infect. Dis. Rep. (1999) 1:427–433.
  • •A good review on the hepatobiliary and pulmonary flukes.
  • UPATHAM ES, VIYANANT V: Opisthorchis viverrini and opisthorchiasis: a historical review and future perspective. Acta Trop. (2003) 88:171–176.
  • •A concise review on opisthorchiasis with an exceedingly good section on diagnostic issues.
  • RADOMYOS P, BUNNAG D, HARINASUTA T: Worms recovered in stools following praziquantel treatment. Arzneimittelforschung (1984) 34:1215–1217.
  • RIM HJ, CHAI JY, MIN DY et al.: Prevalence of intestinal parasite infections on a national scale among primary schoolchildren in Laos. Parasitol. Res. (2003) 91:267–272.
  • SRIPA B: Pathobiology of opisthorchiasis: an update. Acta Trop. (2003) 88:209–220.
  • SRIAMPORN S, PISANI P, PIPITGOOL V, SUWANRUNGRUANG K, KAMSA-ARD S, PARKIN DM: Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop. Med. Int. Health (2004) 9:588–594.
  • • A large-scale study that confirms the positive significant association between O. viverrini infection and cholangiocarcinoma at the population level in northeast Thailand.
  • SALEHA AA: Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance. Southeast Asian J. Trop. Med. Public Health (1991) 22:361–364.
  • HUFFMAN JE, FRIED B: Echinostoma and echinostomiasis. Adv. Parasitol. (1990) 29:215–269.
  • GRACZYK TK, FRIED B: Echinostomiasis: a common but forgotten food-borne disease. Am. J. Trop. Med. Hyg. (1998) 58:501–504.
  • HASEEB MA, EVELAND LK: Human echinostomiasis: mechanisms of pathogenesis and host resistance. In: Echinostomes as Experimental Models for Biological Research. Fried B, Graczyk TK (Eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (2000).
  • JAMORNTHANYAWAT N: The diagnosis of human opisthorchiasis. Southeast Asian J. Trop. Med. Public Health (2002) 33:86–91.
  • MALEEWONG W: Recent advances in diagnosis of paragonimiasis. Southeast AsianJ. Trop. Med. Public Health (1997) 28:134–138.
  • DE NV, MURRELL KD, CONG LE D et al.: The food-borne trematode zoonoses of Vietnam. Southeast Asian J. Trop. Med. Public Health (2003) 34:12–34.
  • HONG ST, RIM HJ, MIN DY et al.:Control of clonorchiasis by repeated treatments with praziquantel. Korean J. Parasitol. (2001) 39:285–292.
  • MAIRIANG E, MAIRIANG P: Clinical manifestation of opisthorchiasis and treatment. Acta Bop. (2003) 88:221-227. Southeast Asian I Bop. Med. Public Health (1991) 22:206–211.
  • CARNEY WP: Echinostomiasis – a snailborne ntestinal trematode zoonosis. Southeast Asian J. Trop. Med. Public Health (1991) 22:206–211.
  • RIM HJ: The current pathobiology and chemotherapy of clonorchiasis. Korean J. Parasitol. (1986) 24:1–141.
  • GROLL E: Praziquantel. Adv. Pharmacol Chemother: (1984) 20:219–238.
  • •A good paper with a concise history of the discovery of praziquantel and early
  • CIOLI D, PICA-MATTOCCIA L: Praziquantel. Parasitol Res. (2003) 90\(Suppl. 1):S3–S9.
  • •A concise article covering all pertinent emphasis on schistosomiasis.
  • GONNERT R, ANDREWS P: Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd.
  • THOMAS H, GONNERT R: The efficacy of praziquantel against cestodes in animals. Z Parasitenkd. (1977) 52:117–127.
  • WEGNER DH: The profile of the trematodicidal compound praziquantel. Arzneimittelforschung (1984) 34:1132-1136. Arzneimittelforschung (1984) 34:1215–1217.
  • RIM HJ, LYU KS, LEE JS, J00 KH: Clinical evaluation of the therapeutic efficacy of praziquantel (Embay 8440) against Clonorchis sinensis infection in man. Ann. Trop. Med. Parasitol (1981) 75:27–33.
  • HONG ST, LEE SH, LEE SJ et al: Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs. Parasitol Res. (2003) 91:316–320.
  • DAVIS A, WEGNER DH: Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull. World Health Organ. (1979) 57:767–771.
  • BUNNAG D, HARINASUTA T: Studieson the chemotherapy of human opisthorchiasis: III. Minimum effective dose of praziquantel. Southeast Asian .1. Trop. Med. Public Health (1981) 12:413–417.
  • JONG EC, WASSERHEIT JN, JOHNSON RI et al.: Praziquantel for the treatment of Clonorchis/Opisthorchis infections: report of a double-blind, placebo-controlled trial. J. Infect. Dis. (1985) 152:637-640. YANGCO BG, DE LERMA C, LYMAN GH, PRICE DL: Clinical study evaluating efficacy of praziquantel in clonorchiasis. Antimicrob. Agents Chemother: (1987) 31:135-138. NA BANGCHANG K, KARBWANG J, PUNGPAK S, RADOMYOS B, BUNNAG D: Pharmacokinetics of praziquantel in patients with opisthorchiasis. Southeast Asian.! Trop. Med. Public Health (1993) 24:717–723.
  • TINGA N, DEN, VIEN HV et al: Little effect of praziquantel or artemisinin on clonorchiasis in Northern Vietnam. A pilot study. Trop. Med. Int. Health (1999) 4:814–818.
  • KIEU TL, BRONSHTEIN AM, SABGAIDA TP: Clonorchiasis in the People's Republic of Vietnam. 2. The clinico-parasitological examination of a focus and a trial of praziquantel treatment. Med. Parazitol. (Murk) (1992) 4:7–11.
  • PUNGPARK S, BUNNAG D, HARINASUTA T: Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections. Southeast Asian J. Trop. Med. Public Health (1984) 15:44–50.
  • LIU YH, WANG XG, GAO P, QIAN MX: Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. ChM. Med. J. (1991) 104:27–31.
  • JAROONVESAMA N, CHAROENLARP K, CROSS JH: Treatment of Opisthorchis viverrini with mebendazole. Southeast Asian I Trop. Med. Public Health (1981) 12:595–597.
  • LI Y, WU YL: An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional chinese herb. Carr: Med. Chem. (2003) 10:2197–2230.
  • •An in-depth review on the artemisinins.
  • UTZINGERJ, XIAO SH, N'GORAN EK, BERGQUIST R, TANNER M: The potential of artemether for the control of schistosomiasis. Int. I Parasitol (2001) 31:1549–1562.
  • SCHIAPPACASSE RH, MOHAMMADI D, CHRISTIE Al: Successful treatment of severe infection with Fasciola hepatica with praziquantel. I. Infect. Dis. (1985) 152:1339–1340.
  • FARAG HF, RAGAB M, SALEM A, SADEK N: A short note on praziquantel in human fascioliasis. I Trop. Med. Hyg. (1986) 89:79–80.
  • FARID Z, KAMAL M, MANSOUR N: Praziquantel and Fasciola hepatica infection. Trans. R. Soc. Bop. Med. Hyg. (1989) 83:813.
  • FARAG HF, SALEM A, EL-HIFNI SA, KANDIL M: Bithionol (Bitin) treatment in established fascioliasis in Egyptians. J. Bop. Med. Hyg. (1988) 91:240–244.
  • APT W, AGUILERA X, VEGA F et al: Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am. I Bop. Med. Hyg. (1995) 52:532–535.
  • ROBINSON CP: Triclabendazole. Drugs Today (1985) 21:227–233.
  • •A comprehensive review on the veterinary use of triclabendazole.
  • SAVIOLI L, CHITSULO L, MONTRESOR A: New opportunities for the control of fascioliasis. Bull. World Health Organ. (1999) 77:300.
  • JAVE OJ, ALBAN OM, SAGASTEGUI PC, SORIANO YS: Treatment of human hepatic Fasciolasis with triclabendazole. Rev Castroenterol Peru (1999) 19:216–220.
  • EL-MORSHEDY H, FARGHALY A, SHARAF S, ABOU-BASHA L, BARAKAT R: Triclabendazole in the treatment of human fascioliasis: a community-based study. East. Mediterr. Health J. (1999) 5:888–894.
  • MILLAN JC, MULL R, FREISE S, RICHTER J: The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am. I Bop. Med. Hyg. (2000) 63:264–269.
  • EL-KARAKSY H, HASSANEIN B, OKASHA S, BEHAIRY B, GADALLAH I: Human fascioliasis in Egyptian children: successful treatment with triclabendazole. Bop. Pediatr. (1999) 45:135–138.
  • LECAILLON JB, GODBILLON J, CAMPESTRINI J et al.: Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br. J. Clin. Pharmacol (1998) 45:601–604.
  • RICHTER J, KNIPPER M, GOEBELS K, HAEUSSINGER D: Fascioliasis. Carr: Treat. Options Infect. Dis. (2002) 4:313–317.
  • •This is an excellent review on fascioliasis with a focus on treatment and clinical procedures.
  • RICHARD-LENOBLE D, CHANDENIER J, DUONG TH: Antiparasitic treatments in pregnant women and in children in 2003. Med. Trop. (2003) 63:491–497.
  • ROBINSON MW, TRUDGETT A, HOEY EM, FAIRWEATHER I: The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res. (2003) 91:117–129.
  • MANSOUR-GHANAEI F, SHAFAGHI A, FALLAH M: The effect of metronidazole in treating human fascioliasis. Med. Sci. Monit. (2003) 9:127–130.
  • ROBINSON MW, LAWSON J, TRUDGETT A, HOEY EM, FAIRWEATHER I: The comparative metabolism of triclabendazole sulphwdde by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res. (2004) 92:205–210.
  • DUGERNIER T, GEUBEL A, BIGAIGNON G, CESBRON JY, COCHE E: Human fascioliasis: cure by mebendazole? A case report. Castroenterol Clin. Biol. (1986) 10:513–516.
  • VERA MONTENEGRO Y, IBARRA VELARDE F, LIEBANO HERNANDEZ E et al.: Efficacy of an experimental fascioficide against immature and mature Fasciola hepatica in artificially infected calves. Parasitol Res. (2004) 92:211–214.
  • NIK-AKHTAR B, TABIBI V: Metronidazole in fascioliasis: report of four cases. J. Bop. Med. Hyg. (1977) 80:179–180.
  • ROSSIGNOL JF, ABAZA H, FRIEDMAN H: Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Bop. Med. Hyg. (1998) 92:103–104.
  • FAVENNEC L, JAVE ORTIZ J, GARGALA G et al.: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther. (2003) 17:265–270.
  • KIM JS: Mass chemotherapy in the controlof paragonimiasis. Korean I Parasitol (1969) 7:6–14.
  • RIM HJ, CHANG YS, LEE JS, J00 KH,SUH WH, TSUJI M: Clinical evaluation of praziquantel (Embay 8440; Biltricide (R)) in the treatment of Paragonimus westermani. Korean! Parasitol (1981) 19:27–37.
  • CALVOPINA M, GUDERIAN RH, PAREDES W, CHICO M, COOPER PJ: Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans. R. Soc. Bop. Med. Hyg. (1998) 92:566–569.
  • RIPERT C, COUPRIE B, MOYOU R, GAILLARD F, APPRIOU M, TRIBOULEY-DURET J: Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. Trans. R. Soc. Bop. Med. Hyg. (1992) 86:417.
  • GAO J, LIU Y, WANG X, HU P: Triclabendazole in the treatment of Paragonimiasis skrjabini. ChM. Med. (2003) 116:1683–1686.
  • SUNTHARASAMAI P, BUNNAG D, TEJAVANIJ S et al.: Comparative clinical trials of niclosamide and tetrachlorethylene in the treatment of Fasciolopsis buski infection. Southeast Asian J. Bop. Med. Public Health (1974) 5:556–559.
  • IDRIS M, RAHMAN KM, MUTTALIB MA, AZAD KHAN AK: The treatment of fasciolopsiasis with niclosamide and dichlorophen. I Bop. Med. Hyg. (1980) 83:71–74.
  • RABBANI GH, GILMAN RH, KABIR I, MONDEL G: The treatment of Fasciolopsis buski infection in children: a comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene. Trans. R. Soc. Bop. Med. Hyg. (1985) 79:513–515.
  • BUNNAG D, RADOMYOS P, HARINASUTA T: Field trial on the treatment of fasciolopsiasis with praziquantel. Southeast Asian J. Bop. Med. Public Health (1983) 14:216–219.
  • RIM HJ, CHU DS, LEE JS, J00 KH, WON CY: Anthelmintic effects of various drugs against metagonimiasis. Korean Parasitol (1978) 16:117–122.
  • ATA AA, ATTIA M, SOLIMAN HM et al: Effect of praziquantel on Heterophyes heterophyes. I Egypt. Soc. Parasitol (1988) 18:515–518.
  • EL-HAWY AM, SAFVVAT M, EL-NASR SSet al.: The cure rates of patients infected with heterophyiasis and treated with praziquantel versus niclosamide.f Egypt. Soc. Parasitol (1988) 18:437–442.
  • MOLYNEUX DH, BRADLEY M, HOERAUF A, KYELEM D, TAYLOR MJ: Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol (2003) 19:516–522.
  • MICHAEL E, MALECELA-LAZARO MN, SIMONSEN PE et al.: Mathematical modelling and the control of lymphatic filariasis. Lancet Infect. Dis. (2004) 4:223–234.
  • HORTON J: Human gastrointestinal helminth infections: are they now neglected diseases? Trends Parasitol (2003) 19:527–531.
  • REICH MR, GOVINDARAJ R: Dilemmas in drug development for tropical diseases. Experiences with praziquantel. Health Policy (1998) 44:1–18.
  • ••An excellent analysis of the interactionsamong key factors affecting the availability and price of praziquantel over time in different markets.
  • REICH MR: The global drug gap. Science (2000) 287:1979–1981.
  • BUTT AA, ALDRIDGE KE, SANDERS CV: Infections related to the ingestion of seafood. Part II: Parasitic infections and food safety. Lancet Infect. Dis. (2004) 4:294–300.
  • KAFERSTEIN F, ABDUSSALAM M: Food safety in the 21st century. Bull. World Health Organ. (1999) 77:347–351.
  • BUNNAG D, PUN GPARK S, HARINASUTA T et al.: Opisthorchis viverrini: clinical experience with praziquantel in Hospital for Tropical Diseases. Arzneimittelforschung (1984) 34:1173–1174.
  • CHEN CY, HSIEH WC: Clonorchis sinensis: epidemiology in Taiwan and clinical experience with praziquantel. Arzneimittelforschung (1984) 34:1160–1162.
  • BUNNAG D, HARINASUTA T: Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel. Southeast Asian .1. Bop. Med. Public Health (1980) 11:528–531.
  • BENJAPONG W, NAEYPATIMANOND S, BENJAPONG K, THUMARUKSA C, RUTTARASARN S, JAROONVESAMA N: Studies on paragonimiasis: treatment with mebendazole, emetine with mebendazole and praziquantel. SoutheastAsianj Trnp. Med. Public Health (1984) 15:354–359.
  • HARINASUTA T, PUNGPAK S, KEYSTONE JS: Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect. Dis. Clin. North Am. (1993) 7:699–716.
  • •An excellent paper providing answers to many clinical questions of trematode infections.
  • HARINASUTA T, BUNNAG D, RADOMYOS P: Efficacy of praziquantel on fasciolopsiasis. Arzneimittelforschung (1984) 34:1214–1215.
  • ORTIZ P, CABRERA M, JAVE J, CLAXTON J, WILLIAMS D: Human fascioliasis: prevalence and treatment in a rural area of Peru. Infect. Dis. Rev (2000) 2:42–46.
  • TAWATSIN A, SIRISINHA S, VAJRASTHIRA S, BUNNAG D, HARINASUTA T: Evaluation of selected anthelmintic compounds for activity against Opisthorchis viverrini. Tropenmed. Parasitol (1984) 35:85–90.
  • BHAIBULAYA M, PUNTHUPRAPASA P: Treatment of Opisthorchiasis viverrini in hamsters with albendazole. Southeast Asian J. Bop. Med. Public Health (1984) 15:389–393.
  • IBARRA OF, JENKINS DC: An in vitro screen for new fasciolicidal agents. Z Parasitenkd. (1984) 70:655–661.
  • BUCHANAN JF, FAIRWEATHER I, BRENNA GP, TRUDGETT A, HOEY EM: Fasciola hepatica: surface and internal tegumental changes induced by treatment in vitro with the sulphoxide metabolite of albendazole ('Valbazen). Parasitology (2003) 126:141–153.
  • RONALD NC, CRAIG TM, BELL RR: A controlled evaluation of albendazole against natural infections with Fasciola hepatica and Fascioloides magna in cattle. Am. Vet. Res. (1979) 40:1299–1300.
  • DUBEY JP, HOOVER EA, STROMBERG PC, TOUSSANT MJ: Albendazole therapy for experimentally induced Paragonimus kellicotti infection in cats. Am.j Vet. Res. (1978) 39:1027–1031.
  • LIU Y, GAO J, WANG X, YU D, SU Q: Experimental observation of effects of triclabendazole on Paragonimus westermani infection in dogs. ChM. Med. (1999) 112:345–348.
  • MAURER K, DECERE M, FRIED B: Effects of the anthelmintics clorsulon, rafoxanide, mebendazole and arprinocid on Echinostoma caproni in ICR mice. Helminthol (1996) 70:95–96.

Websites

  • http://mednet3.who.indeml/disease_factsheet. asp?diseaseId=204

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.